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Abstract
Background and Objective ‘Natural selection’ has been
shown to have enriched the genomes of high-altitude native
populations with genetic variants of advantage in this
hostile hypoxic environment. In lowlanders who ascend to
altitude, genetic factors may also contribute to the sub-
stantial interindividual variation in exercise performance
noted at altitude. We performed a systematic literature
review to identify genetic variants of possible influence on
human hypoxic exercise performance, commenting on the
strength of any identified associations.
Criteria for considering studies for this review All stud-
ies of the association of genetic factors with human hy-
poxic exercise performance, whether at sea level using
‘nitrogen dilution of oxygen’ (normobaric hypoxia), or at
altitude or in low-pressure chambers (field or chamber
hypobaric hypoxia, respectively) were sought for review.
Search strategy for identification of studies Two elec-
tronic databases were searched (Ovid MEDLINE, Embase)
up to 31 January 2014. We also searched the reference lists
of relevant articles for eligible studies. All studies pub-
lished in English were included, as were studies in any
language for which the abstract was available in English.
Data collection and analysis Studies were selected and
data extracted independently by two reviewers. Differences
regarding study inclusion were resolved through discus-
sion. The quality of each study was assessed using a
scoring system based on published guidelines for con-
ducting and reporting genetic association studies.
Results A total of 11 studies met all inclusion criteria and
were included in the review. Subject numbers ranged from
20 to 1,931 and consisted of healthy individuals in all
cases. The maximum altitude of exposure ranged from
2,690 to 8,848 m. The exercise performance phenotypes
assessed were mountaineering performance (n = 5), run-
ning performance (n = 2), and maximum oxygen con-
sumption ( _VO2max) (n = 4). In total, 13 genetic
polymorphisms were studied, four of which were associ-
ated with hypoxic exercise performance. The adenosine
monophosphate deaminase (AMPD1) C34T (rs17602729),
beta2-adrenergic receptor (ADRB2) Gly16Arg single nu-
cleotide polymorphism (SNP) (rs1042713), and androgen
receptor CAG repeat polymorphisms were associated with
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altitude performance in one study, and the angiotensin
I-converting enzyme (ACE) insertion/deletion (I/D)
(rs4646994) polymorphism was associated with perfor-
mance in three studies. The median score achieved in the
study quality analysis was 6 out of 10 for case–control
studies, 8 out of 10 for cohort studies with a discrete out-
come, 6 out of 9 for cohort studies with a continuous
outcome, and 4.5 out of 8 for genetic admixture studies.
Conclusion The small number of articles identified in the
current review and the limited number of polymorphisms
studied in total highlights that the influence of genetic
factors on exercise performance in hypoxia has not been
studied in depth, which precludes firm conclusions being
drawn. Support for the association between the ACE-I al-
lele and improved high-altitude performance was the
strongest, with three studies identifying a relationship.
Analysis of study quality highlights the need for future
studies in this field to improve the conduct and reporting of
genetic association studies.
Key Points
The size and scope of the literature regarding the role
of genetics on high-altitude exercise performance is
limited.
The association between the angiotensin
I-converting enzyme (ACE) insertion (I) allele and
improved high-altitude performance has the
strongest support.
The volume and quality of the literature limits firm
conclusions being made and needs to be addressed in
future studies.
1 Introduction
With ascent to altitude, barometric pressure falls, and with
it the partial pressure of inspired oxygen (PiO2). Despite
diverse adaptive responses, the arterial partial pressure of
oxygen (PaO2) also falls. Such ‘hypobaric hypoxia’ impairs
physical performance and can cause pathology (acute
mountain sickness [AMS]), which may be fatal (e.g. high-
altitude pulmonary oedema [HAPE] or high-altitude cere-
bral oedema [HACE]).
Longstanding communities of high-altitude residents
exist worldwide, most notably on the Tibetan Plateau and
Andean Altiplano, but also in the area of the Great Rift
Valley in Ethiopia. ‘Natural selection’ has enriched the
genomes of high-altitude native populations, conferring
advantage in this hostile hypoxic environment [1]. Mean-
while, increasing numbers of native lowlanders travel to
high altitudes for recreation or work. Amongst these low-
land populations, similar genetic factors may contribute to
the substantial inter-individual variation in exercise per-
formance and wellbeing observed at altitude [2, 3]. Whilst
attempts have been made to identify genetic variants as-
sociated with improved high-altitude performance, the re-
sults of such studies have yet to be collated. We thus set out
to systematically review the published literature and
identify genetic variants of influence on human hypoxic
exercise performance, commenting on the strength of any
identified associations.
2 Methods
2.1 Search Strategy
2.1.1 Criteria for Considering Studies for this Review
All studies of the association of genetic factors with human
hypoxic exercise performance, whether at sea level using
‘nitrogen dilution of oxygen’ (normobaric hypoxia), or at
altitude or in low-pressure chambers (field or chamber
hypobaric hypoxia, respectively) were sought for review.
‘Altitude’ was defined as a real or simulated (normobaric
hypoxia) elevation of C2,000 m above sea level. Perfor-
mance measures were defined as any measure of aerobic
exercise capacity (such as _VO2max or _VO2peak) or of
exercise performance (e.g. a timed physical challenge).
Studies were included if they evaluated exercise perfor-
mance under conditions of hypoxia or changes in sea-level
performance following hypoxic exposure. Case–control
studies were included where cases were successful per-
formers at[2,000 m, and where appropriate control groups
(by race and by similar altitude of origin [±500 m]) were
utilised. Only human studies and full primary research
papers (e.g. not a conference abstract, letter to the editor, or
review) were eligible for inclusion. Studies of high-altitude
population genetics per se were excluded unless
specifically assessing a physical performance phenotype.
Research articles were excluded if they did not seek to
identify genetic factors and their relationship with hypoxic
exercise performance.
2.1.2 Search Strategy for Identification of Studies
The following electronic databases were searched: Ovid
MEDLINE Daily Update \31 January 2014[, Ovid
OLDMEDLINE\1946 to 1965[, Ovid MEDLINE In-
Process and Other Non-Indexed Citations, Ovid
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MEDLINE \1946 to present[ and Embase Clas-
sic ? Embase \1947 to 31 January 2014[. Ovid MED-
LINE is produced by the National Library of Medicine and
indexes information from approximately 5,600 journals in
the fields of biomedicine and related fields. Embase is an
Elsevier database that indexes biomedical and pharmaco-
logical bibliographic records from articles published in
more than 7,500 peer-reviewed journals. The search in-
cluded all studies published in English and studies in any
language for which the abstract was available in English.
No other limits were applied.
We developed a search strategy based on the ‘patient or
population, intervention, comparison, outcome’ (PICO)
framework. However, the types of study we sought do not
conform exactly to the PICO format, which could not
therefore be fully adhered to. In particular, all populations
were eligible for inclusion, making the ‘patient or
population’ parameter redundant. In order to formulate a
research question, each search contained one term from
each of the following three parameters (intervention,
comparison, and outcome) with each term linked by the
Boolean operator ‘AND’. The full search strategy run in
the various databases can be found in Electronic Supple-
mentary Material Appendix S1 and Appendix S2. In brief,
the key terms used in the search are listed hereafter, and
these were also used to identify synonyms and related
terms (which were also searched for):
• Intervention: Altitude, anoxia, or hypoxia.
• COMPARISON: Gene frequency, genotype, polymor-
phism, haplotype, single nucleotide polymorphism, or
genetic linkage.
• Outcome: Exercise tolerance, exercise test, exercise,
athletic performance, performance, mountaineering,
summit, physical endurance, endurance.
2.1.3 Searching Other Resources
In addition to electronic databases, we searched bibli-
ographies of included articles for research papers. Research
papers with titles that indicated that the study was in the
scope of the current review were retrieved and underwent
the formal review process.
2.1.4 Data Collection and Analysis
In the first stage of the review process, two authors (PJH,
AFO) independently inspected all citations from the
searches (using information contained in the title, key-
words and abstract) to identify candidate articles for which
full texts were retrieved. If any ambiguity arose regarding
the inclusion or exclusion of an article due to the absence
of key information, the full-text article was obtained. In the
second stage, the authors (PJH, AFO) independently ap-
plied the inclusion and exclusion criteria to the candidate
full-text articles. At both stages of the process, differences
regarding study inclusion were resolved through
discussion.
2.1.5 Data Extraction and Management
From each source document, the lead author (PJH) ex-
tracted data including study identification information,
number of participants in each group, demographic in-
formation (including the sex, age and ethnicity, race or
origin of the participants), magnitude of hypoxic expo-
sure (altitude or hypoxic exposure), polymorphism and/or
gene or region being studied, gene and allele frequen-
cies, probability values from comparisons, measure of
performance, and the information required to assess the
quality of each study (see Table 1). Studies were
separated according to their primary study design (case–
control or cohort). Odds ratios (ORs) were determined
for studies with categorical outcomes variables using an
additive model.
2.2 Study Quality Analysis
The quality of each study was assessed using a scoring
system (Table 1) adapted from Clark and Baudouin [4],
which was based on published guidelines for conducting
and reporting genetic association studies. Different aspects
of the study were scored 1 if the information was present or
0 if it was not. These were then summed to give a final
score that ranged from 0 to 10 for case–control studies, 0–9
for cohort studies, and 0–8 for genetic admixture studies.
We modified the approach of Clark and Baudouin [4] in
relation to sample size and power calculations. Studies
were deemed adequate in this respect if a power calculation
was reported, but we did not perform a power calculation
for studies where this was not reported. The criteria used
for considering the quality of the control group were also
adapted. In the original system by Clark and Baudouin [4],
a study that used a control group from a previously pub-
lished study would need to describe the population in
sufficient detail to meet the study quality criteria to score.
Due to word restrictions imposed by publishers and the
need to avoid repetition, we extended this. In studies that
provided a reference to a control population, the referenced
study was retrieved and the control group analysed ac-
cording to the original criteria. We also altered the methods
used to assess the reproducibility of genotyping to allocate
a score both to studies that provided their own validation
results and to those that provided a reference to a study
using the same procedures that included validation
information.
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3 Results
3.1 Results of the Search
The initial search identified 307 articles (see Fig. 1). After
removing duplicate articles, 213 remained for the first
evaluation. Following review of the title, abstract and
keywords of these records, 12 candidate articles were
identified that met the predefined criteria, and full-text
versions were obtained for further review. Four candidate
articles did not meet the review inclusion criteria and were
therefore rejected, leaving eight eligible articles for ap-
praisal [5–12]. Examination of the full-text version of these
articles and their bibliographies identified three additional
eligible articles [13–15]. A total of 11 articles were in-
cluded in the final analysis.
3.2 Description of Included Studies
The 11 studies reviewed can be separated into those
comparing the frequency of genotypes or alleles between
two groups (case–control) (Table 2) [6, 15]; cohort studies
where participants were separated according to task suc-
cess or failure and where genotype or allele frequencies
were compared between groups (Table 3) [8–10]; and
cohort studies comparing the difference in performance
measures (continuous variable) between individuals
grouped by genotype or allele (Table 4) [6, 7, 11, 12]. Two
studies used a different approach, and examined whether
Spanish compared with Quechua genetic admixture ex-
plained differences in _VO2max at high altitude [13, 14].
According to the location of the corresponding author,
studies were from the UK (n = 4), the USA (n = 3),
Greece (n = 1), New Zealand (n = 1), South Africa
(n = 1), and China (n = 1). The number of subjects in
each study varied from 20 to 1,931, and consisted of
healthy males in four studies [12–15] and healthy males
and females in six studies [5, 7–11], with sex of the par-
ticipants not stated in one study [6]. The maximum altitude
of exposure ranged from 2,690 to 8,848 m. The exercise
performance phenotype assessed was mountaineering per-
formance in five studies [6, 8–10, 15], running performance
in two studies [7, 11] and maximum oxygen consumption
in four studies [5, 12–14]. In total, 13 genetic polymor-
phisms located within ten different genes were studied,
excluding those used to estimate genetic admixture by
Brutsaert and colleagues [13, 14]. The most studied gene
was that encoding the angiotensin I-converting enzyme
(ACE), which was studied in seven separate papers. The
names of all the genes studied, excluding those used to
Table 1 Study quality scoring assessment system
Item Criterion
1. Control group Was the control/comparison group equal or larger in size than the case group, and was it
• described in such a way that it could be replicated;
• stated or inferred that the ethnicity of the control group was not different to that of the case group.
If the control group from a previous study was used and referenced, the referenced study was retrieved and the
control group analysed as above. No score was assigned to cohort studies for this item
2. Hardy–Weinberg
equilibrium
Were the groups included in the study assessed for to determine whether they were in Hardy–Weinberg
equilibrium?
3. Case group/whole
group
Is the definition of the case group adequate to allow replication?
For cohort studies, is the description of the whole group sufficient for replication?
4. Primer Were the primer sequences provided or was a reference to these given?
5. Reproducibility of
genotyping
Was the description of genotyping methods sufficient to allow replication or was a reference providing this
information given? And, was the validity of the genotyping technique checked by performing a second assay
technique, by validating the accuracy of the assay used, or was a reference to a validation study given?
6. Blinding Were genotyping staff blinded from group allocation or phenotypic data?
7. Power calculation Was a power calculation performed either prospectively or retrospectively?
8. Statistics Were major findings presented with well described tests of significance including p values, odds ratios or confidence
intervals?
9. Corrected statistics When more than one genetic polymorphism was studied, were statistical corrections made to account for the
increased risk of a false positive?a One-tailed significance testing was also scored as zero. Those testing one
genetic polymorphism were scored as one
10. Independent
replication
Was a secondary confirmatory study performed, or does the study specifically state it is being performed to confirm
results from an earlier study?
Items were scored ‘1’ for yes and ‘0’ for no
a If the study only investigated one genetic polymorphism, the question was scored as ‘1’
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indicate Quechua and Spanish ancestry by Brusaert and co-
workers [13, 14], are listed in Table 5 along with the
symbols and the chromosomal location. Results are pre-
sented according to the genetic polymorphism of interest,
then by phenotype of interest (given sub-heading where
necessary), and are ordered based on the maximum altitude
studied.
3.3 Angiotensin-Converting Enzyme (ACE) Insertion/
Deletion (I/D) Polymorphism (rs4646994)
Seven studies investigated the association of the ACE I/D
(rs4646994) polymorphism with exercise performance at
altitude. Two were case–controlled studies that compared
genotype or allele frequencies between high-altitude
mountaineers and a control population (Table 2). Five
cohort studies were also conducted; in three of these, study
participants were separated according to task success or
failure, and genotype and/or allele frequencies were com-
pared between groups (Table 3), whilst two studies com-
pared performance phenotype (as a continuous variable
[e.g. time and _VO2max]) between those of different
genotype (Table 4).
3.3.1 Mountaineering Performance
In a prospective study, Tsianos et al. [10] reported the ACE
I-allele to be associated with successful ascent of Mont
Blanc (4,807 m). ACE genotype distribution varied be-
tween Caucasian climbers who successfully summited Mt
Blanc (n = 183) and those who tried and failed (n = 12)
(p = 0.048) (OR 3.41), the I allele being more prevalent in
those who summited than in those who did not (0.47 vs
0.21, p = 0.01) (Table 3). The proportion of those of each
genotype who successfully summited was 87.7, 94.9 and
100 % for the DD, ID, and II genotypes, respectively.
Kalson et al. [8] prospectively studied Caucasian trek-
kers attempting to climb Mt Kilimanjaro (5,895 m), par-
ticipants being separated by ascent rate (4 days [‘direct’]
vs. 5 days [‘slow’]). Genotype distribution did not differ by
success rate in the ‘slow’ group (II: 9 [0.22], ID: 18 [0.44],
DD: 14 [0.34] successful versus II: 9 [0.22], ID: 22 [0.54],
DD: 10 [0.24] unsuccessful, p = 0.54; I allele frequency
0.44 vs. 0.49, respectively; OR 0.82). In ‘fast ascent’
subjects, ACE genotype distribution was II: 6 (0.30) vs. ID:
11 (0.55) vs. DD: 3 (0.15) in those who were successful
and II: 0 (0.00) vs. ID: 10 (0.71) vs. DD: 4 (0.29) in those
who failed (p = 0.09). I-allele frequency for those who
were successful versus those who failed was 0.58 vs. 0.36
(OR 2.44) (Table 3).
Montgomery et al. [15] studied ACE genotype in 25
elite British high-altitude mountaineers who had frequently
ascended beyond 7,000 m without supplementary oxygen.
When compared with 1,906 British controls (free from
clinical cardiovascular disease), the I allele was found to be
over-represented in cases (p = 0.003), as was the ACE II
Arcles idenﬁed through database searching
(n = 307)
Arcles for inial inspecon aer duplicates 
removed (n = 213)
Arcles included in the review from the 
database search (n = 8)
Full text arcles reviewed (n = 12)
Total number of arcles included in review
(n = 11)
Arcles added aer 
bibliography search (n = 3)
Arcles excluded following 
inial review of tle, abstract 
and keywords (n = 201)
Arcles excluded following 
full text review (n = 4)
Fig. 1 Search methodology and results
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genotype (proportion 0.48 vs. 0.23 in cases vs. controls,
respectively) (OR 2.43) (Table 2). The DD genotype was
not present in any individual who had previously ascended
beyond 8,000 m.
Djarova et al. [6] also reported I allele prevalence to be
greater in five elite Bulgarian mountaineers (all climbed
above 7,500 m without supplementary oxygen) than in 72
Bulgarian student controls (0.60 vs. 0.41, respectively;
p = 0.002) (OR 2.29). ACE genotype distribution differed,
largely due to an excess of ID genotype in the elite group
(p = 0.024) (Table 2). The small case population (n = 5)
limits confidence in this finding. Further, we were unable to
replicate their statistical analysis: using the ACE allele
frequencies and population numbers stated in the paper,
and applying Fisher’s exact test (as the authors did) in a
commonly used statistical package (SPSS 21 [IBM, Ar-
monk, NY, USA]), we were unable to demonstrate a sta-
tistically significant difference in ACE allele frequencies
between the two groups (p = 0.203). The same held true
for the two other polymorphisms they studied, which were
the alpha actinin-3 ACTN3 R577X (rs1815739) and the
adenosine monophosphate deaminase (AMPD1) C34T
polymorphisms (rs17602729).
Thompson et al. [9] extended the observations of Tsia-
nos et al. [10], Kalson et al. [8] and Montgomery et al. [15]
to individuals attempting to climb beyond 8,000 m, also
noting the maximum altitude attained by each individual
and the reason for failure. Once again, in a population of
Caucasian and Asian mountaineers, ACE genotype distri-
bution differed between successful summiteers (n = 92)
and those who failed (n = 57) (OR 2.15) (Table 3)
(p = 0.003). Both II genotype and the I allele were more
prevalent in the successful group (II genotype 0.33 vs. 0.06
[p = 0.003]; I allele, 0.55 vs. 0.36 for success vs failure,
respectively). Maximum altitude attained (as a continuous
variable) was also related to ACE I allele, being 8,079 vs.
8,107 and 8,559 m for those of DD, ID and II genotype,
respectively (allele comparison, p = 0.0023).
3.3.2 Maximum Oxygen Uptake ( _VO2max) at Altitude
Bigham et al. [5] reported the relationship of ACE geno-
type with _VO2max at 4,338 m in Peruvian high-altitude
native residents (n = 74) and in Peruvian low-altitude
residents whose family originate from high altitude
(n = 68). _VO2max did not differ by genotype, even when
other cofactors, such as altitude of residence, were ac-
counted for (Table 4).
3.3.3 Sea-Level Running Performance
Hinckson et al. [7] studied whether improvement in sea-
level exercise performance following hypoxic exposure
(2,500–3,500 m) was related to ACE genotype (Table 4).
This study was primarily designed to test the efficacy of
hypoxic training for improving running performance. It
included a study group whose ten participants were ex-
posed to 4 weeks of hypoxia for [10 h per day, and ten
controls who had no hypoxic exposure. In eight par-
ticipants (ethnicity not disclosed) in the study group, the
relationship between improvements in running perfor-
mance following hypoxic training with ACE I/D genotype
was sought (Table 3). However, neither numerical results
by genotype nor statistical analysis are reported—although
a figure suggests a lack of genotype association.
3.4 ACTN3 R577X (rs1815739)
Two studies tested whether an association was present
between the ACTN3 R577X polymorphism and high-alti-
tude exercise performance. Tsianos et al. [11] included the
ACTN3 RX polymorphism as one of 11 polymorphisms (in
eight genes) for which an association was sought with
performance in the Mt Olympus Marathon (maximum
altitude of 2,690 m). In all, no such association was iden-
tified in 438 participants over 2 years of racing. The dis-
tribution of the ACTN genotypes in the small elite high-
Table 5 Symbols, names, and chromosomal location of all genes identified
Gene Name Location
ACE Angiotensin 1-converting enzyme 17q23
ACTN3 Actinin, alpha 3 11q13–q14
ADRB2 Adrenergic, beta 2, receptor 5q31–q32
AMPD1 Adenosine monophosphate deaminase 1 1p13
APOE Apolipoprotein E 19q13.2
AR Androgen receptor Xq11–12
BDKRB2 Bradykinin receptor B2 14q32.1–q32.2
PPARA Peroxisome proliferative activated receptor, alpha 22q13.31
PPARD Peroxisome proliferative activated receptor, delta 6p21.2–p21.1
PPARGC1A Peroxisome proliferative activated receptor, gamma, coactivator 1, alpha 4p15.1
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altitude mountaineer cohort (n = 5) tested by Djarova
et al. [6] was RR 1 (0.20), RX 3 (0.60), and XX 1 (0.20)
compared with RR 30 (0.42), RX 32 (0.44) and XX 10
(0.14) in the control group (n = 72). The allele frequencies
between the two groups were different (p = 0.032), with a
relative excess of the X allele in the mountaineers (OR
1.77) (Table 2). However, as discussed in the previous
section, the statistical approach of Djarova et al. [6] was of
questionable validity. Using the allele frequencies and
subject numbers from the paper [6], we found no difference
in the ACTN RX allele distributions between the two
populations (p = 0.501).
3.5 AMPD1 C34T (rs17602729)
In the study by Tsianos et al. [11] (see previous section),
the AMPD C34T polymorphism was not associated with
Mt Olympus Marathon performance for the whole group
studied, but subgroup analysis revealed a modest asso-
ciation between the T allele (referred to as the ‘A allele’ in
Tsianos et al. [11]) and better performance in athletes
whose preferred sport was running (event completion time,
p = 0.021; best ever time, p = 0.03). Djarova et al. [6]
found that the frequency of the T allele was higher in
mountaineers than in controls (p = 0.032; OR 2.82)
(Table 2). However, as stated in the previous two results
sections, the statistical analysis in this study is incorrect;
using the reported allele frequencies in a Fisher’s test, we
found no difference in the distribution of the allele of the
AMPD1 C34T polymorphism between the elite moun-
taineers and controls (p = 0.155).
3.6 Other Polymorphisms
Ten other polymorphisms were studied. Of nine studied by
Tsianos et al. [11] (listed in Table 4), the beta2-adrenergic
receptor (ADRB2) Gly16Arg single nucleotide polymor-
phism (SNP) (rs1042713) was associated with performance
in the Mt Olympus Marathon. In the study by Tsianos et al.
[11], the Arg allele was associated with a shorter time to
complete the race amongst people who chose running as
their preferred exercise mode (p = 0.015), and with best
ever Mt Olympus Marathon time for those who had com-
pleted the event multiple times (p = 0.003). Meanwhile,
Wang et al. [12] studied the association between the an-
drogen receptor (AR) CAG repeat polymorphism and
_VO2max changes in 65 unrelated Han Chinese college
athletes following a 30-day bout of intermittent hypoxic
exposure, consisting of 10 h a day of sleeping at 14.8–
14.3 % O2 (simulating 2,800–3,000 m altitude), 30-minute
exercise bouts at 15.4 % O2 (simulating 2,500 m altitude)
three times per week, and additional sea-level training.
They found that individuals with the lowest number of
CAG repeat units (B21) had a greater increase in _VO2max
following hypoxic training than those with a higher number
of repeats ([21) (D _VO2max; B21 CAG repeats 11.9 %
increase,[21 CAG repeats 3.6 % increase; p = 0.004).
3.7 High-Altitude Population Ancestry
Two papers from the same group measured a number of
physiological variables, including _VO2max, at altitude in
Peruvian males of mixed Quechua and Spanish origins [13,
14]. Both sought to determine whether individuals with
stronger Quechua (historical long-term high-altitude resi-
dent) origins had favourable physiological responses to
altitude. We considered excluding these two papers as,
strictly speaking, they do not meet one of the inclusion
criteria: to ‘seek to identify genetic factors.’ However, we
did include them given that they studied exercise perfor-
mance at altitude and separated individuals based on their
genetic profile. The first, published in 2004, comprised two
groups from Peru; a group resident in Lima (sea level) and
a group resident in Cerro de Pasco (4,388 m) [13]. No
association was found between _VO2max values at an alti-
tude of 4,388 m, and the degree of Quechua, Spanish and
African ancestry, as indicated by 22 genetic markers. The
second study [14] used the same lowland population and
the same genetic profiling as the 2004 study [13] (con-
firmed with primary author of the manuscripts via email
correspondence) and analysed the influence of genetic ad-
mixture on the magnitude of the _VO2max decrement from
sea level to high altitude (data not presented in the same
author’s 2004 paper). After controlling for other covariates,
genetic admixture explained a significant proportion of the
variation (b -0.205) in the decrement in _VO2max from sea
level to high altitude (p = 0.041), with those with a higher
Quechua (and lower Spanish) genetic ancestry maintaining
sea-level _VO2max values to a greater degree.
3.8 Study Quality
As the method of assessing study quality is not validated
and may only provide a guide to the quality of reporting of
the research, we have not commented on each study indi-
vidually. Instead, we aim to identify trends in the available
literature where the conduct and/or reporting of research
could be improved. The median score achieved in the study
quality analysis was 6 out of 10 for case–control studies, 8
out of 10 for cohort studies with a discrete outcome, 6 out
of 9 for cohort studies with a continuous outcome, and 4.5
out of 8 for genetic admixture studies (Table 6). The study
quality score ranged considerably between studies, for
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example in cohort studies with a continuous outcome the
total score ranged from 2 to 7 out of 9.
In the case–control studies, the descriptions of the case
groups were adequate, with both the studies given a score
of 1 [6, 15]. However, only one of the control groups was
deemed adequate [15], with the other study failing to
provide adequate information about whether the level of
relatedness of participants was controlled [6]. The majority
of studies in which testing for Hardy–Weinberg (HW)
equilibrium was appropriate did so (seven of eight). The
one study that did not test for HW equilibrium had very
small subject numbers (n = 8) and so it would have pro-
vided very little information [7]. In the other three studies,
two investigated whether genetic admixture was associated
with performance. This approach utilised polymorphisms
that differed according to ancestry, meaning that testing for
HW equilibrium would be uninformative [13, 14]. In the
other study, the polymorphism was located on the X
chromosome, and the populations were male, so genotype
distribution would not conform with HW equilibrium,
evidence of which was thus not sought [12].
Three study quality criteria relate to genotyping methods
and reporting: providing the sequence of primers, demon-
strating the reproducibility of the genotyping methods, and
adequately blinding the genotyping staff from the pheno-
type details. Most studies (7 of 11) provided the details of
the primer sequence (or a reference to them), one stated
that this would be made available on request [11], two gave
reference to a website that could be used to identify them
[13, 14], and one failed to provide any information [7].
Eight studies stated that they had validated their genotyp-
ing methods or cited a reference for a validation study,
while only two studies stated that their genotyping staff
were blinded from the phenotype data.
The statistical merit of each paper was analysed in three
of the study quality criteria. These analysed whether ap-
propriate statistical tests were performed, whether adjust-
ments were made to account for multiple comparisons in
studies analysing more than one polymorphism, and whe-
ther power calculations were made. Ten of the 11 studies
used appropriate formal methods of comparison to estab-
lish whether difference were present between groups. Only
one study did not use a formal test of significance, and this
was probably justified because the small number of par-
ticipants would have precluded any meaningful results
being obtained [7]. Only one study analysed several poly-
morphisms and failed to make adjustments for multiple
comparisons [6]. Four of the 11 studies conducted sample
size calculations [6, 8, 11, 13], with one study performing
the calculation prior to conducting the study [11].
No article included in the review provided both a study
identifying a potential polymorphism and a study validat-
ing the original finding. Following the original paper
analysing the association between the ACE I/D polymor-
phism and mountaineering performance by Montgomery
et al. [15], several other papers analysed the association
between this polymorphism and highly related phenotypes
[6, 8–10]. Furthermore, one study replicated polymor-
phisms related to endurance performance at sea level using
an endurance race at altitude as the phenotype [11].
4 Discussion
4.1 Main Findings
This review identified four genetic polymorphisms asso-
ciated with hypoxic exercise performance: AMPD1 C34T,
ADRB2 GA, AR CAG repeat, and the ACE I/D poly-
morphisms. Support for the association between the ACE I
allele and high-altitude performance was the strongest,
with three studies identifying a positive relationship be-
tween the I allele and improved performance. Conversely,
the AMPD1 34T allele and the ADRB2 16Arg allele were
associated with better performance in atmospheric hypoxia
in one study, while those with the lowest number of CAG
repeat units in the AR had better _VO2max gains following
hypoxic training in one study. This review identified that
the number of articles and the total number of polymor-
phisms studied within this area are few; only 11 articles
were identified and only 13 polymorphisms within ten
different genes studied. In addition, the conduct and/or
reporting of the studies was not optimal, with many failing
to select and describe the populations adequately, several
not conducting or describing their genotyping methods
sufficiently and many conducted without calculating the
correct sample size required to adequately power the study.
4.2 Study Number and Design
The small number of articles identified in the current re-
view and the limited number of polymorphisms studied in
total highlights that the influence of genetic factors on
exercise performance in hypoxia has not been studied in
depth. This is in contrast to the hundreds of articles that
have studied the influence of genetics on other phenotypes
such as exercise performance at sea level [16]. The ma-
jority of studies have taken the candidate gene approach
(n = 9), whilst two studied whether genetic admixture in-
fluenced exercise performance [13, 14]. The limited range
of SNPs studied is likely due to a bias towards studying
genes associated with exercise and/or altitude phenotypes
in previous publications and to the reliance on the candi-
date gene approach. The absence of genome-wide asso-
ciation studies is notable, as it would allow hypothesis-free
investigation and help identify novel candidate genes for
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which the biological pathway is not known. This approach
is commonplace in many other fields of research and has
been used successfully to identify polymorphisms associ-
ated with _VO2max gains at sea level [17], obesity [18] and
blood pressure [19]. The candidate gene approach is jus-
tified, as it has greater power to detect difference in
genotype frequency between groups, and is suited to
studies using modest population sizes [20]. Despite most
studies using the candidate gene method, study designs
differed greatly with regards to the population, hypoxic
exposure, and the performance phenotype. The small
number of studies, in addition to the variety of study de-
signs, makes comparison between studies difficult, and
limits the ability to assess the reliability of results. The
variety of study designs, polymorphisms and outcomes
studied, and the small number of studies, precluded
meaningful formal assessment of bias, such as a funnel plot
[21]. That said, in spite of small sample sizes, seven of the
nine candidate gene studies identified an association be-
tween a polymorphism and the performance phenotype
with effect sizes considered very large for genetic asso-
ciation studies [22]. These factors may point towards some
form of bias within the literature base, although this cannot
be confirmed at this time.
4.3 Genetic Polymorphisms Associated with Exercise
Performance during Hypoxic Exposure
This review identified four polymorphisms associated with
exercise performance in a hypoxic environment, and found
nine polymorphisms to have no relationship (Tables 3, 4,
5). Furthermore, in a study of Peruvian natives, a genetic
profile with a greater Quechua (as opposed to Spanish)
origin was associated with greater preservation of _VO2max
at altitude [14].
4.4 ACE I/D Polymorphism (rs4646994)
The ACE I/D polymorphism had the most supporting lit-
erature, with three studies observing an association of the I
allele (lower ACE activity) with mountaineering perfor-
mance [9, 10, 15]. ACE is an important component of the
endocrine renin-angiotensin system (RAS), converting an-
giotensin I to angiotensin II, which exerts pressor effects
through arteriolar vasoconstriction and aldosterone-medi-
ated salt and water retention [23]. However, cellular and
tissue RAS are now known to exist in multiple tissues [23],
where they have diverse roles relating to the regulation of
cell growth and survival, metabolism and inflammation
[24]. The presence (insertion, I-allele) rather than absence
(deletion, D-allele) of a 287 bp fragment in the ACE gene
(rs4646994) is associated with lower circulating [25] and
tissue [26, 27] ACE activity. Whilst the mechanism un-
derpinning the association between the ACE I/D poly-
morphism and mountaineering performance has yet to be
fully established, the I allele has been associated with en-
hanced endurance performance at sea level [28], greater
hypoxic ventilatory drive [29], enhanced arterial oxy-
genation at altitude [30], and enhanced training-related
gains in metabolic efficiency [31].
It should be noted that three studies found no association
between the ACE ID polymorphism and their hypoxic
exercise performance phenotype of interest [5, 7, 8] and
one presented incorrect results [6]. The others found no
ACE genotype association with _VO2max at 4,338 m in
Peruvian natives [5] or change in endurance running per-
formance following hypoxic training [7]. However, this
later study had limited power to detect any difference in
genotype distribution due to a very small sample size.
These results are important in their own right, but it is
entirely plausible that an association exists between the
ACE polymorphism and mountaineering performance that
is mediated by a mechanism unrelated to _VO2max. The
lack of association between the polymorphism and moun-
taineering performance in the study by Kalson et al. [8] is
more difficult to explain. However, despite the altitude
exposure and performance phenotype being similar in all
four studies, there are still subtle differences in ascent rate,
maximum altitude of exposure and total time at high alti-
tude, which may explain the discrepancy. Furthermore,
Kalson et al. [8] acknowledged that they had insufficient
sample size to detect a difference between successful and
unsuccessful climbers and were therefore at risk of a type 2
error. The lack of power due to small sample size is a
limitation of many of the reviewed studies and will be
discussed further in the ‘Study Quality’ section.
4.5 ACTN3 R577X (rs1815739)
The ACTN3 gene encodes the protein alpha actinin-3, an
actin-binding protein expressed predominantly in type II
(fast) muscle fibres, which has structural, cell signalling
and metabolic roles [32, 33]. The ACTN3 gene contains a
nonsense polymorphism that results in the substitution of
an arginine (R) with a stop codon (X) at amino acid 577 on
the alpha actinin-3 protein (rs1815739) [34]. The prema-
ture termination of the alpha actinin-3 protein associated
with homozygosity for the R577X null allele results in
complete alpha actinin-3 deficiency, and occurs in ap-
proximately 16 % of the world population [34]. Whilst this
deficiency does not cause muscle disease, possibly due to
compensation by the closely related isoform alpha actinin-
2, it does appear to influence sporting performance [32].
The frequency of the ACTN3 alleles was reported to differ
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between a ‘normal’ population, an elite sprint and power
athletic population, and an elite endurance athletic
population (p\ 0.001), with elite power athletes having a
lower frequency of the XX genotype (normal 18 %; elite
power 6 %) and elite endurance athletes having a higher
frequency of XX genotype (normal 0.16; elite endurance
0.24) [35]. The two studies identified in our review do not
support an association between the ACTN3 R577X poly-
morphism and exercise performance at high altitude [6,
11]. However, given the limited performance phenotypes
investigated and the flawed statistical analysis in the study
by Djarova et al. [6], an association cannot be excluded.
4.6 AMPD1 C34T (rs17602729)
AMPD catalyses the conversion of adenosine monophos-
phate (AMP) to inosine monophosphate (IMP) and am-
monia which, in turn, moves the myokinase equilibrium
reaction (2 ADP  ATP ? AMP) towards ATP re-syn-
thesis [36]. The AMPD1 gene contains a genetic variation
(C34T) that results in the replacement of a glutamine
amino acid with a stop codon and has an allele frequency of
13.7 % in a healthy Caucasian population [37]. Norman
et al. [37] also showed that AMPD activity in skeletal
muscle of AMPD1 TT homozygotes was\1 % that of CC
homozygotes, and that heterozygotes had intermediate ac-
tivity levels. At sea level, the AMPD1 TT homozygotes
have been shown to have *14 % lower peak power output
than their CT/CC counterparts (p\ 0.05) [38], and the
frequency of the T allele is lower in elite endurance ath-
letes than in controls (0.043 vs. 0.085; p\ 0.05) [39].
Tsianos et al. [11] also found an association between the
AMPD T allele and Mt Olympus Marathon performance in
athletes whose preferred endurance sport was running. It is
thus unclear whether AMPD1 genotype is associated with
endurance performance per se or with hypoxic endurance
performance. No data are available to answer this question.
The results must be viewed with some caution, as they
were obtained in a sub-population of the whole group
studied and are yet to be verified in other high-altitude
exercise phenotypes (we do not consider the results of
Djarova et al. [6] valid).
4.7 Other Polymorphisms
The adrenergic receptors are G protein-coupled receptors
that are expressed in a wide range of tissues and cause a
variety of physiological responses in response to binding
with circulating catecholamines [40]. The ADRB2 sub-
group has a primary function to facilitate a sympathetic
nervous system response, altering respiratory, cardiac and
vascular function [41]. In a meta-analysis, the pooled fre-
quency of the ADRB2 minor (16Arg) allele was 0.420 in
Caucasians, 0.492 among populations with an African
heritage (African-American, African and Afro-Caribbean
populations) and 0.562 among Oriental populations [42].
The ADRB2 polymorphism alters physiological function;
compared with their ADRB2 Gly/Gly counterparts, 16Arg
homozygotes have lower receptor density on isolated
lymphocytes [43], lower resting stroke volume and cardiac
output [43, 44], and lower sub-maximal exercising stroke
volume and mean arterial pressure [44]. Furthermore, the
Arg/Arg genotype was more prevalent in an elite male
endurance athlete population than in a control population
consisting of geographically matched males (0.17 vs. 0.09,
p = 0.03).
This review identified one study in which the ADRB2
Arg allele was associated with better endurance exercise
performance at altitude. Tsianos et al. [11] found the Arg
allele was associated with better performance in the Mt
Olympus Marathon amongst people whose preferred mode
of exercise was running, and with best ever Mt Olympus
Marathon time amongst those who had completed the event
several times. As described in the previous section re-
garding similar results for the AMPD1 C34T SNP, these
results should be viewed with caution given that these as-
sociations were established for particular subgroups and
were only sought and identified in one study. However (and
again as described above), the results are aligned with
those obtained at sea level, which increases the confidence
in the validity of such findings.
Androgens, such as testosterone, act by binding to the
AR, and their effects on anthropometric variables and
physical performance (including increasing fat free mass,
muscle strength and size) are well described [45]. In
skeletal muscle cells, the AR CAG repeat polymorphism
alters the receptor’s transcriptional activity, with higher
repeat lengths causing greater activity, as well as altering
markers of cell growth and development [46]. Wang et al.
[12] identified an association between those with a lower
number of CAG repeat units (B21) and a greater increase
in _VO2max following hypoxic training. However, a nor-
moxic control population was not employed and therefore
the increases in _VO2max, and the association with the AR
polymorphism, may simply reflect a training effect. Further
studies designed to distinguish the effect of training from
that of hypoxia are required.
4.8 High-Altitude Population Ancestry
The two related studies by Brutsaert and colleagues [13,
14] found no association between the degree of Quechua,
Spanish and African ancestry in a population of Peruvian
males, as indicated by 22 genetic markers and _VO2max
values at an altitude of 4,388 m. However, they did find
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that the magnitude of the decrease in _VO2max from sea
level to high altitude was lower in those with a greater
degree of Quechua ancestry. The specific mechanisms to
explain this exercise performance phenotype are not read-
ily forthcoming as the data in this field are sparse; however,
a genetically mediated reduction in arterial oxygen
saturation (SaO2) during maximal exercise appears to have
a role [14]. This finding adds to a growing body of lit-
erature suggesting that the Quechua have altered anthro-
pological and physiological responses to hypoxia as a
result of genetic selection [47].
4.9 Study Quality
Analysis of study quality highlights a need for better
conduct and/or reporting of genetic association studies in
this field. The selection of populations, genotyping prac-
tices, and statistical procedures were inadequate in many of
the studies (Table 6), and only three studies attempted to
replicate prior findings using similar phenotypes [8–10].
Some studies did not ensure that ethnicity of populations
was accounted for in the analysis process, country of origin
often being an inadequate descriptor. Selecting unrelated
populations of the same ethnicity is critical to avoid
population stratification, which can confound results and
lead to spurious association being identified [48]. However,
such problems are hard to overcome in ‘field’ research.
Poor genotyping practices may also lead to erroneous re-
sults and can be caused by many factors including col-
lecting low quality and/or quantity of DNA, machine error
or failure, human error, poor storage conditions, and issues
with the array [49]. Despite this, only eight studies stated
that they had checked the validity of their genotyping
procedure or cited a reference for a validation study [5, 9–
12, 14, 15], and only two blinded genotyping staff from
phenotypic data [8, 9]. Meanwhile, seven studies provided
sufficient primer information to allow replication. Seven of
the 11 studies failed to conduct sample size calculations,
and only one study performed the calculation prior to
conducting the study. The majority of studies included in
the review seem underpowered to test their hypothesis ef-
fectively as the associations between SNPs and complex
human phenotypes, such as exercise performance, are
generally small [22]. The studies in this review typically
had a sample size of under 100, whereas it has been sug-
gested that to adequately power genetic association studies
investigating complex multifactorial traits, studies should
employ sample sizes well in excess of this number [22].
Finally, replication of initial findings is of paramount im-
portance because a first study often overestimates the size
of the effect when compared with subsequent studies, and
in many cases the subsequent studies fail to support the
initial findings [50]. The studies we reviewed failed to
validate initial findings by testing the same genetic poly-
morphism on a similar population and phenotype. How-
ever, the association between the ACE polymorphism and
mountaineering performance identified by Montgomery
et al. [15] was evaluated in similar populations in three
subsequent studies, albeit using different study designs [8–
10].
4.10 Strengths and Limitations of the Review
The strengths of this review are that it used systematic
search and analysis methodologies to identify studies that
have investigated the association between genetic factors
and exercise performance in atmospheric hypoxia. This
allowed us to identify all studies in the area and avoided
selection bias. Identifying these polymorphisms will guide
future research, identifying targets for further study and
helping to avoid the repetition of work. The review also
analysed the conduct and/or reporting of the studies, giving
an indication of study quality and highlighting where im-
provements in study design can be made.
Limitations of this study include the method of study
selection. It may have been helpful to exclude studies
based on study design and/or quality to provide a clearer
picture of which polymorphisms and molecular systems are
important in hypoxic exercise performance. However, the
lack of a robust validated method of analysing study design
and quality in genetic association studies made this diffi-
cult. Consequently, we adapted Clark and Baudouin’s [4]
method of analysing study quality. This method has not
been validated and thus it is unclear whether it indicates
greater study validity, or the likelihood of replication.
However, it does follow previous studies and articles that
give recommendations for how genetic association studies
should be conducted and presented [51, 52].
5 Conclusions
This review shows that the association between genetic
polymorphisms and high-altitude exercise performance has
not been studied in depth. We identified only 11 articles
that studied a total of just 13 genetic polymorphisms. Four
polymorphisms were associated with hypoxic exercise
performance: AMPD1 C34T, ADRB2 GA, AR CAG re-
peat, and the ACE I/D polymorphisms. The strongest as-
sociation appears to be between the ACE I allele and
enhanced high-altitude mountaineering performance, with
three studies identifying a relationship. The study quality
analysis highlighted deficiencies in the conduct and re-
porting of the genetic association studies. The selection and
description of populations, genotyping methods, and
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statistical analysis procedures were inadequate in many of
the studies. In particular, many studies failed to calculate
the correct sample size required to adequately power their
study and subsequently most appear underpowered to test
their hypothesis effectively. To attain greater understand-
ing of the role that genetic factors have on high-altitude
exercise performance, further studies need to be performed.
Future studies should endeavour to use more robust study
design (e.g. appropriate sample size, replicable phenotypes,
robust methods of selecting study and control populations)
and ensure they provide adequate information to permit
subsequent replication or meta-analysis. Furthermore,
genome-wide studies should be considered in future in
order to help identify novel biological pathways of hypoxic
adaptation.
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